Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 12/2020

Open Access 01-12-2020 | Portal Vein Thrombosis | Liver (Scott C and E Kallwitz, Section Editors)

Causes and Management of Non-cirrhotic Portal Hypertension​

Authors: Stefania Gioia, Silvia Nardelli, Lorenzo Ridola, Oliviero Riggio

Published in: Current Gastroenterology Reports | Issue 12/2020

Login to get access

Abstract

Purpose of the Review

Non-cirrhotic portal hypertension (NCPH) includes a heterogeneous group of conditions. The aim of this paper is to make an overview on the denominations, diagnostical features and management of porto-sinusoidal vascular disease (PSVD) and chronic portal vein thrombosis (PVT) being the main causes of NCPH in the Western world.

Recent Findings

The management of NCPH consists in the treatment of associated diseases and of portal hypertension (PH). PH due to PSVD or PVT is managed similarly to PH due to cirrhosis. TIPS placement and liver transplantation are considerable options in patients with refractory variceal bleeding/ascites and with progressive liver failure. Anticoagulation is a cornerstone both in the treatment of thrombosis in PSVD and in the prevention of thrombosis recurrence in patients with portal cavernoma.

Summary

Physicians should be aware of the existence of PSVD and chronic PVT and actively search them in particular settings. To now, the management of portal hypertension-related complications in NCPH is the same of those of cirrhosis. Large cooperative studies on the natural history of NCPH are necessary to better define its management.
Literature
1.
Sarin SK, Kumar A. Noncirrhotic portal hypertension. Clin Liver Dis. 2006;10:627–51.PubMed
2.
Schouten JNL, Garcia-Pagan JC, Valla DC, Janssen HLA. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54:1071–81.PubMed
3.
• Valla DC, Cazals-Hatem D. Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts. Virchows Arch. 2018;473(1):3–13 One of the most recent and exhaustive review on vascular liver diseases.PubMed
4.
•• De Gottardi A, Rautou PE, Schouten J. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019;4(5):399–411 On behalf of VALDIG, the authors proposed a new terminology to refer to idiopathic non-cirrhotic portal hypertension in order to include also patients with typical histological features of the disease but no clinical portal hypertension.PubMed
5.
Cazals-Hatem D, Hillaire S, Rudler M, Plessier A, Paradis V, Condat B, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol. 2011;54(3):455–61.PubMed
6.
Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology. 2014;59:2276–85.PubMed
7.
Guido M, Sarcognato S, Sonzogni A, Lucà MG, Senzolo M, Fagiuoli S, et al. Obliterative portal venopathy without portal hypertension: an underestimated condition. Liver Int. 2016;36(3):454–60.PubMed
8.
•• Gioia S, Nardelli S, Pasquale C, et al. Natural history of patients with non-cirrhotic portal hypertension: comparison with patients with compensated cirrhosis. Dig Liver Dis. 2018;50(8):839–44 One of the recent few studies comparing natural history of NCPH (porto-sinusoidal vascular disease and chronic portal vein thrombosis) with natural history cirrhosis.PubMed
9.
Seijo S, Reverter E, Miquel R, Berzigotti A, Abraldes JG, Bosch J, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis. 2012;44:855–60.PubMed
10.
Riggio O, Gioia S, Pentassuglio I, Nicoletti V, Valente M, d'Amati G. Idiopathic noncirrhotic portal hypertension: current perspectives. Hepat Med. 2016;8:81–8.PubMedPubMedCentral
11.
• Guido M, Alves VAF, Balabaud C, Bathal PS, Bioulac-Sage P, Colombari R, et al. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. Histopathology. 2019;74:219–26 Clear review aiming to make order among the numerous definitions and histological characteristics of PSVD.PubMed
12.
Glatard AS, Hillaire S, d’Assignies G, Cazals-Hatem D, Plessier A, Valla DC, et al. Obliterative portal venopathy: findings at CT imaging. Radiology. 2012;263:741–50.PubMed
13.
Krishnan P, Fiel MI, Rosenkrantz AB, Hajdu CH, Schiano TD, Oyfe I, et al. Hepatoportal sclerosis: CT and MRI appearance with histopathologic correlation. AJR Am J Roentgenol. 2012;198:370–6.PubMed
14.
Vuppalanchi R, Mathur K, Pyko M, Samala N, Chalasani N. Liver stiffness measurements in patients with noncirrhotic portal hypertension-the devil is in the details. Hepatology. 2018;68:2438–40.PubMed
15.
Gioia S, Nardelli S, Riggio O. Letter to the editor: liver stiffness in noncirrhotic portal hypertension: the devil is in the diagnosis. Hepatology. 2019;70:444–5.PubMed
16.
Futagawa S, Fukazawa M, Musha H, Isomatsu T, Koyama K, Ito T, et al. Hepatic venography in noncirrhotic idiopathic portal hypertension. Comparison with cirrhosis of the liver. Radiology. 1981;141:303–9.PubMed
17.
Okuda K, Kono K, Ohnishi K, Kimura K, Omata M, Koen H, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology. 1984;86:600–10.PubMed
18.
EASL Clinical Practice Guidelines. Vascular diseases of the liver. J Hepatol. 2016;64(1):179–202.
19.
20.
de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.PubMed
21.
Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol. 2000;32(5):865–71.PubMed
22.
Bradbury MS, Kavanagh PV, Chen MY, Weber TM, Bechtold RE. Non-invasive assessment of Porto-mesenteric venous thrombosis: current concepts and imaging strategies. J Comput Assist Tomogr. 2002;26:392–404.PubMed
23.
Ueno N, Sasaki A, Tomiyama T, Tano S, Kimura K. Color Doppler ultrasonography in the diagnosis of cavernous transformation of the portal vein. J Clin Ultrasound. 1997;25:227–33.PubMed
24.
Vilgrain V, Condat B, Bureau C, Hakime A, Plessier A, Cazals-Hatem D, et al. Atrophy-hypertrophy complex in patients with cavernous transformation of the portal vein: CT evaluation. Radiology. 2006;241:149–55.PubMed
25.
Dhiman RK, Saraswat VA, Valla DC, Chawla Y, Behera A, Varma V, et al. Portal cavernoma cholangiopathy: consensus statement of a working party of the Indian national association for study of the liver. J Clin Exp Hepatol. 2014;4:S2–S14.PubMedPubMedCentral
26.
Plessier A, Darwish MS, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51:210–8.PubMed
27.
Orr DW, Harrison PM, Devlin J, Karani JB, Kane PA, Heaton ND, et al. Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long-term follow-up. Clin Gastroenterol Hepatol. 2007;5:80–6.PubMed
28.
Gioia S, Nardelli S, Ridola L, d'Amati G, Riggio O. Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis? World J Hepatol. 2019;11(8):613–8.PubMedPubMedCentral
29.
Sarin SK, Wadhawan M, Gupta R, Shahi H. Evaluation of endoscopic variceal ligation (EVL) versus propranolol plus isosorbide mononitrate/nadolol (ISMN) in the prevention of variceal re- bleeding: comparison of cirrhotic and noncirrhotic patients. Dig Dis Sci. 2005;50:1538–47.PubMed
30.
Sarin SK, Gupta N, Jha SK, Agrawal A, Mishra SR, Sharma BC, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology. 2010;139:1238–45.PubMed
31.
Lv Y, Li K, He C, Luo B, Zhang B, Liu H, et al. TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosis. Aliment Pharmacol Ther. 2019;49(7):926–39.PubMed
32.
Bissonnette J, Garcia-Pagán JC, Albillos A, Turon F, Ferreira C, Tellez L, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension: liver failure/cirrhosis/portal hypertension. Hepatology. 2016;64(1):224–31.PubMed
33.
Fanelli F, Angeloni S, Salvatori FM, Marzano C, Boatta E, Merli M, et al. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis. 2011;43:78–84.PubMed
34.
Marot A, Barbosa JV, Denys A, Deltenre P. A new classification of chronic portal vein occlusion for assessing the feasibility of recanalization in non-cirrhotic patients. J Hepatol. 2017;66(suppl. 1):S 133.
35.
Schouten JN, Nevens F, Hansen B, Laleman W, van den Born M, Komuta M, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther. 2012;35:1424–33.PubMed
36.
Rangari M, Gupta R, Jain M, Malhotra V, Sarin SK. Hepatic dysfunction in patients with extrahepatic portal venous obstruction. Liver Int. 2003;23:434–9.PubMed
37.
Nicoletti V, Gioia S, Riggio O, et al. Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: description, prevalence and risk factors. Dig Liv Dis. 2016;48(9):1072–7.
38.
Minguez B, Garcia-Pagan JC, Bosch J, Turnes J, Alonso J, Rovira A, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology. 2006;43:707–14.PubMed
39.
Marin D, Galluzzo A, Plessier A, Brancatelli G, Valla D, Vilgrain V. Focal nodular hyperplasia-like lesions in patients with cavernous transformation of the portal vein: prevalence, MR findings and natural history. Eur Radiol. 2011;21:2074–82.PubMed
40.
Lattanzi B, Gioia S, Di Cola S, et al. Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension. Liver Int. 2019;39(10):1937–42.PubMed
41.
Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;11:627–34 discussion 610-621.PubMed
42.
Dumortier J, Bizollon T, Scoazec JY, Chevallier M, Bancel B, Berger F, et al. Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome. Scand J Gastroenterol. 2001;36:417–22.PubMed
43.
Loinaz C, Colina F, Musella M, Lopez-Rios F, Gomez R, Jimenez C, et al. Orthotopic liver transplantation in 4 patients with portal hypertension and non-cirrhotic nodular liver. Hepatogastroenterology. 1998;45:1787–94.PubMed
44.
Amitrano L, Guardascione MA, Scaglione M, Pezzullo L, Sangiuliano N, Armellino MF, et al. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol. 2007;102:2464–70.PubMed
45.
Spaander MC, Hoekstra J, Hansen BE, van Buuren HR, Leebeek FW, Janssen HL. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11:452–9.PubMed
46.
Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 2001;120:490–7.PubMed
47.
Acosta S, Alhadad A, Verbaan H, Ogren M. The clinical importance in differentiating portal from mesenteric venous thrombosis. Int Angiol. 2011;30(1):71–8.PubMed
48.
Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP, et al. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut. 2001;49:720–4.PubMedPubMedCentral
49.
Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474–80.PubMed
50.
• De Gottardi A, Trebicka J, Klinger C, et al. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int. 2017;37(5):694–9 One of the few papers evaluating the use of DOACs in patients with cirrhotic and non-cirrhotic splanchnic vein thrombosis. DOACs seems to be effective and safe in these patients.PubMed
51.
Steuber TD, Howard ML, Nisly SA. Direct oral anticoagulants in chronic liver disease. Ann Pharmacother. 2019;53(10):1042–9.PubMed
52.
Priyanka P, Kupec JT, Krafft M, Shah NA, Reynolds GJ. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis. Int J Hepatol. 2018;2018:8432781.PubMedPubMedCentral
Metadata
Title
Causes and Management of Non-cirrhotic Portal Hypertension​
Authors
Stefania Gioia
Silvia Nardelli
Lorenzo Ridola
Oliviero Riggio
Publication date
01-12-2020
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 12/2020
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-020-00792-0

Other articles of this Issue 12/2020

Current Gastroenterology Reports 12/2020 Go to the issue

Endoscopy and Surgery (S Komanduri, Section Editor)

Determining the Indeterminate Biliary Stricture: Cholangioscopy and Beyond

Endoscopy and Surgery (S Komanduri, Section Editor)

Endobariatrics and Metabolic Endoscopy: Can We Solve the Obesity Epidemic with Our Scope?

Endoscopy and Surgery (S Komanduri, Section Editor)

Endoscopic Eradication Therapy for Barrett’s Neoplasia: Where Do We Stand a Decade Later?

Endoscopy and Surgery (S Komanduri, Section Editor)

Advances in Biliary Access

Endoscopy and Surgery (S Komanduri, Section Editor)

Emerging Therapies to Prevent Post-ERCP Pancreatitis

Inflammatory Bowel Disease (M Regueiro, Section Editor)

Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits